PRV-3279

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NamePRV-3279
Drug Alias NameAnti-CD32B-anti-CD79B-bispecific-monoclonal-antibodyMGD-010PRV-3279CD32BxCD79BHDM-3002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor II-b antagonistsAnti-CD79B
TargetsLow affinity immunoglobulin gamma Fc region receptor II-bB-cell antigen receptor complex-associated protein beta chain
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoHong Kong +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProvention Bio IncMacrogenics IncHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A